BACKGROUND: T cells play an important part in Crohn's disease. Immunomodulating therapies that target T cell activation may have clinical effects in Crohn's disease. AIM: To investigate the toxicity and potential efficacy of anti-CD4 monoclonal antibody therapy in patients with Crohn's disease. PATIENTS AND METHODS: A dose escalating pilot study was conducted in three groups of four patients with intractable Crohn's disease, refractory to steroids. They received 70, 210, or 700 mg of cM-T412, a depleting anti-CD4 monoclonal antibody (mAb). RESULTS: The mean reduction in Crohn's disease activity index (CDAI) was respectively 25%, 24%, and 36% at four weeks, and 24% and 52% at 10 weeks in the 210 mg and 700 mg groups. There was only a minor effect on endoscopically evaluated disease activity. Side effects were mild to moderate fever with chills and headache. No signs of opportunistic infection were seen. There was a sustained decrease in CD4 count which lasted at least four weeks in the 70 mg group (76.3 (SD 40.6)% of the baseline value), and 10 weeks in both the 210 mg group (80.8 (SD 60.9)%) and the 700 mg group (24.8 (SD 15.4)%). The primary and secondary humoral immune response was not influenced by anti-CD4 mAb treatment. CONCLUSION: This study shows the moderate potential efficacy of treatment of patients with Crohn's disease using a depleting chimeric monoclonal anti-CD4 antibody.
BACKGROUND: T cells play an important part in Crohn's disease. Immunomodulating therapies that target T cell activation may have clinical effects in Crohn's disease. AIM: To investigate the toxicity and potential efficacy of anti-CD4 monoclonal antibody therapy in patients with Crohn's disease. PATIENTS AND METHODS: A dose escalating pilot study was conducted in three groups of four patients with intractable Crohn's disease, refractory to steroids. They received 70, 210, or 700 mg of cM-T412, a depleting anti-CD4 monoclonal antibody (mAb). RESULTS: The mean reduction in Crohn's disease activity index (CDAI) was respectively 25%, 24%, and 36% at four weeks, and 24% and 52% at 10 weeks in the 210 mg and 700 mg groups. There was only a minor effect on endoscopically evaluated disease activity. Side effects were mild to moderate fever with chills and headache. No signs of opportunistic infection were seen. There was a sustained decrease in CD4 count which lasted at least four weeks in the 70 mg group (76.3 (SD 40.6)% of the baseline value), and 10 weeks in both the 210 mg group (80.8 (SD 60.9)%) and the 700 mg group (24.8 (SD 15.4)%). The primary and secondary humoral immune response was not influenced by anti-CD4 mAb treatment. CONCLUSION: This study shows the moderate potential efficacy of treatment of patients with Crohn's disease using a depleting chimeric monoclonal anti-CD4 antibody.
Authors: R Q Hintzen; R de Jong; C E Hack; M Chamuleau; E F de Vries; I J ten Berge; J Borst; R A van Lier Journal: J Immunol Date: 1991-07-01 Impact factor: 5.422
Authors: C Herzog; C Walker; W Müller; P Rieber; C Reiter; G Riethmüller; P Wassmer; H Stockinger; O Madic; W J Pichler Journal: J Autoimmun Date: 1989-10 Impact factor: 7.094
Authors: J Brynskov; L Freund; S N Rasmussen; K Lauritsen; O S de Muckadell; N Williams; A S MacDonald; R Tanton; F Molina; M C Campanini Journal: N Engl J Med Date: 1989-09-28 Impact factor: 91.245
Authors: T van der Poll; S J van Deventer; C E Hack; G J Wolbink; L A Aarden; H R Büller; J W ten Cate Journal: Blood Date: 1992-02-01 Impact factor: 22.113
Authors: J Zimmermann; A A Kühl; M Weber; J R Grün; J Löffler; C Haftmann; R Riedel; P Maschmeyer; K Lehmann; K Westendorf; M-F Mashreghi; M Löhning; M Mack; A Radbruch; H D Chang Journal: Mucosal Immunol Date: 2016-02-17 Impact factor: 7.313
Authors: Sun K Lee; Beom K Choi; Young H Kim; Woo J Kang; Kwang H Kim; Shimon Sakaguchi; Jae H Suh; Tae Y Kim; Byoung S Kwon Journal: Immunology Date: 2006-12 Impact factor: 7.397